SARS-CoV-2 刺突治疗性抗体在变异体时代。
SARS-CoV-2 spike therapeutic antibodies in the age of variants.
机构信息
Regeneron Pharmaceuticals Inc., Tarrytown, NY.
出版信息
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20210198.
Abstract
Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.
摘要
再生元制药公司（Regeneron Pharmaceuticals）研究副总裁、传染病和病毒载体技术专家 Christos Kyratsous 与再生元制药公司传染病副总监 Alina Baum 探讨了针对 SARS-CoV-2 刺突蛋白的抗体疗法的研发。
相似文献
1
SARS-CoV-2 spike therapeutic antibodies in the age of variants.SARS-CoV-2 刺突治疗性抗体在变异体时代。
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20210198.
2
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
3
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
4
SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.严重急性呼吸综合征冠状病毒2型抗体：三种高通量免疫测定法与中和试验的比较
Eur J Clin Invest. 2021 Jul;51(7):e13573. doi: 10.1111/eci.13573. Epub 2021 May 5.
5
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.XAV-19，一种针对 SARS-CoV-2 刺突受体结合域的猪源糖基化人源化多克隆抗体，靶向多个表位并广泛中和变异株。
Front Immunol. 2021 Nov 15;12:761250. doi: 10.3389/fimmu.2021.761250. eCollection 2021.
6
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
7
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.恢复期血清和疫苗诱导的抗体对全球 SARS-CoV-2 变体刺突在很大程度上保持中和效价。
mBio. 2021 Jun 29;12(3):e0069621. doi: 10.1128/mBio.00696-21. Epub 2021 Jun 1.
8
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.抗严重急性呼吸综合征冠状病毒 2 超免疫球蛋白通过 N 和 S 蛋白显示出强大的中和作用以及抗体依赖的细胞细胞毒性和吞噬作用。
J Infect Dis. 2022 Mar 15;225(6):938-946. doi: 10.1093/infdis/jiab540.
9
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
10
A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.一种非 RBM 靶向 RBD 特异性抗体中和 SARS-CoV-2 诱导 S1 脱落。
Biochem Biophys Res Commun. 2021 Sep 24;571:152-158. doi: 10.1016/j.bbrc.2021.07.062. Epub 2021 Jul 20.
引用本文的文献
1
Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection.靶向猴痘病毒A29和B6的双特异性抗体对猴痘病毒感染具有疗效。
J Virol. 2025 May 20;99(5):e0232024. doi: 10.1128/jvi.02320-24. Epub 2025 Apr 3.
2
On the collection and integration of SARS-CoV-2 genome data.关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）基因组数据的收集与整合
Biosaf Health. 2023 Jul 4;5(4):204-210. doi: 10.1016/j.bsheal.2023.07.004. eCollection 2023 Aug.
3
Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant.SARS-CoV-2 贝塔变异株中 RBD 突变的独特组合导致抗体逃逸。
J Microbiol Biotechnol. 2023 Dec 28;33(12):1587-1295. doi: 10.4014/jmb.2308.08020. Epub 2023 Nov 3.
4
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.卡西瑞维单抗与英夫维单抗抗体组合在免疫功能低下的2019冠状病毒病住院患者中的有效性：一项1/2/3期双盲试验的事后分析
Open Forum Infect Dis. 2023 Apr 19;10(5):ofad211. doi: 10.1093/ofid/ofad211. eCollection 2023 May.
5
Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.将 SARS-CoV-2 特异性鸡尾酒抗体工程化为双特异性形式可提高中和效力和广度。
Nat Commun. 2022 Sep 22;13(1):5552. doi: 10.1038/s41467-022-33284-y.
6
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.在成年人中重复皮下给予 casirivimab 和 imdevimab 是耐受良好的，并且可预防 COVID-19 的发生。
Int J Infect Dis. 2022 Sep;122:585-592. doi: 10.1016/j.ijid.2022.06.045. Epub 2022 Jul 2.
7
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.针对 SARS-CoV-2 的被动免疫疗法：从基于血浆的疗法到单一强效抗体，以在与变异体的竞赛中保持领先地位。
BioDrugs. 2022 May;36(3):231-323. doi: 10.1007/s40259-022-00529-7. Epub 2022 Apr 27.
8
Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth.将严重急性呼吸综合征冠状病毒2（SARS-CoV-2）鸡尾酒抗体工程化为双特异性形式可提高中和效力和广度。
bioRxiv. 2022 Feb 1:2022.02.01.478504. doi: 10.1101/2022.02.01.478504.
9
Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications.新兴的 SARS-CoV-2 变种：遗传变异性和临床意义。
Curr Microbiol. 2021 Dec 14;79(1):20. doi: 10.1007/s00284-021-02724-1.
10
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.在 21 天内启动 COVID-19 单克隆抗体的比较有效性自适应平台试验。
Contemp Clin Trials. 2022 Feb;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 9.
本文引用的文献
1
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. Reply.皮下注射REGEN-COV抗体组合预防新冠病毒病。回复。
N Engl J Med. 2021 Nov 11;385(20):e70. doi: 10.1056/NEJMc2113862. Epub 2021 Oct 6.
2
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.ChAdOx1新型冠状病毒疫苗对B.1.351变异株的有效性。回复。
N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.
Zotero 插件